AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of “Moderate Buy” by Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has received a consensus rating of “Moderate Buy” from the twelve brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $60.40.

ANAB has been the subject of a number of research reports. UBS Group began coverage on shares of AnaptysBio in a research note on Wednesday, January 7th. They set a “buy” rating and a $70.00 target price for the company. Barclays reduced their price objective on AnaptysBio from $70.00 to $55.00 and set an “overweight” rating for the company in a research report on Wednesday, December 17th. Wedbush reaffirmed an “outperform” rating and issued a $50.00 target price on shares of AnaptysBio in a research report on Monday, November 24th. Guggenheim reaffirmed a “buy” rating on shares of AnaptysBio in a research note on Thursday, December 18th. Finally, Wall Street Zen raised AnaptysBio from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th.

Insider Buying and Selling at AnaptysBio

In other news, CFO Dennis Mulroy sold 2,515 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $44.71, for a total transaction of $112,445.65. Following the transaction, the chief financial officer owned 21,852 shares in the company, valued at $977,002.92. This represents a 10.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Paul F. Lizzul sold 3,650 shares of AnaptysBio stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $44.71, for a total transaction of $163,191.50. Following the completion of the sale, the insider directly owned 42,088 shares of the company’s stock, valued at approximately $1,881,754.48. The trade was a 7.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 135,280 shares of company stock valued at $6,184,409. 33.50% of the stock is currently owned by insiders.

Institutional Trading of AnaptysBio

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. HighMark Wealth Management LLC boosted its holdings in AnaptysBio by 58.2% in the 2nd quarter. HighMark Wealth Management LLC now owns 145,550 shares of the biotechnology company’s stock valued at $3,231,000 after purchasing an additional 53,550 shares during the period. Panagora Asset Management Inc. bought a new position in shares of AnaptysBio during the 2nd quarter worth about $741,000. Allianz Asset Management GmbH bought a new position in shares of AnaptysBio during the 2nd quarter worth about $337,000. Los Angeles Capital Management LLC acquired a new position in shares of AnaptysBio during the second quarter valued at about $334,000. Finally, 683 Capital Management LLC lifted its stake in shares of AnaptysBio by 155.6% in the second quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock valued at $11,100,000 after buying an additional 304,373 shares during the period.

AnaptysBio Price Performance

Shares of ANAB opened at $46.31 on Friday. The business’s 50-day moving average is $43.59 and its 200-day moving average is $32.16. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -16.42 and a beta of 0.32. AnaptysBio has a fifty-two week low of $12.21 and a fifty-two week high of $52.47.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, topping the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The business had revenue of $76.32 million during the quarter, compared to analysts’ expectations of $15.83 million. Equities research analysts expect that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its board has initiated a share buyback plan on Friday, November 21st that allows the company to repurchase $100.00 million in shares. This repurchase authorization allows the biotechnology company to purchase up to 9.6% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.